Alexion Announces Positive Top-Line Results Showing Successful Phase 3 Clinical Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria ...
Alexion Pharmaceuticals, Inc (ALXN)
Last alexion pharmaceuticals, inc earnings: 1/30 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.alexion.com/investor-relations
Company Research
Source: Business Wire
-- ALXN1210 Achieved Non-Inferiority to Soliris® (Eculizumab) on Co-Primary Endpoints of Transfusion Avoidance and Lactate Dehydrogenase Normalization, and All Four Key Secondary Endpoints -- -- Safety Profile of ALXN1210 Consistent with That Seen for Soliris® -- -- Regulatory Submissions Planned in the United States, European Union, and Japan in the Second Half of 2018 -- -- Conference Call/Webcast Scheduled for Today, Thursday, March 15, 2018 at 8:30 a.m. EDT -- NEW HAVEN, Conn.--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced today that the pivotal Phase 3 study of ALXN1210, the Company’s investigational long-acting C5 complement inhibitor, demonstrated non-inferiority to Soliris® (eculizumab) in complement inhibitor treatment-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH) based on the co-primary endpoints of transfusion avoidan
Show less
Read more
Impact Snapshot
Event Time:
ALXN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALXN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALXN alerts
High impacting Alexion Pharmaceuticals, Inc news events
Weekly update
A roundup of the hottest topics